Fresh analysis indicates that patients who discontinue new slimming jabs like semaglutide or tirzepatide may regain shed pounds far faster than those who end conventional lifestyle regimens.
Findings released in a prominent health publication demonstrates that while obese individuals can lose a large proportion of their body weight while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such drugs must be cognizant of the danger of fast rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting weight within about a year and a half.
Analyzing Therapies
The research, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
Scientists note that people who lose weight through dieting usually see a slower weight regain—around 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Doctors propose the way of the drugs explains the heightened weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than normal might result in the body to produce less of its own natural hormone, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating much more probable."
A Chronic Issue?
The NHS advise the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, given the likelihood of weight regain, the treatment is often ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the results "underscore the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Users who have discontinued the medication describe a sudden return of cravings.
"It felt as if something that goes on and you become ravenous," described a patient.
This challenge is worsened if users have not established lasting lifestyle or habit changes during treatment.
Widespread Use
Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a magic fix and long-term success likely depends on ongoing behavioural changes.
